News
OMIC
0.4000
+1.27%
0.0050
Weekly Report: what happened at OMIC last week (0415-0419)?
Weekly Report · 1d ago
Singular Genomics Systems (OMIC) Price Target Increased by 25.93% to 0.87
NASDAQ · 6d ago
Weekly Report: what happened at OMIC last week (0408-0412)?
Weekly Report · 04/15 09:28
Weekly Report: what happened at OMIC last week (0401-0405)?
Weekly Report · 04/08 09:30
Weekly Report: what happened at OMIC last week (0325-0329)?
Weekly Report · 04/01 09:30
Weekly Report: what happened at OMIC last week (0318-0322)?
Weekly Report · 03/25 09:31
Singular Genomics Systems Price Target Raised to $0.50/Share From $0.40 by UBS
Dow Jones · 03/21 19:01
Singular Genomics Systems Is Maintained at Neutral by UBS
Dow Jones · 03/21 19:01
Singular Genomics Faces Nasdaq Delisting: A Race Against Time to Meet Minimum Bid Price
TipRanks · 03/20 06:00
OMIC Stock Earnings: Singular Genomics Sys Beats EPS, Beats Revenue for Q4 2023
Singular Genomics Sys just reported results for the fourth quarter of 2023. The company reported revenue of $1.08 million. Singular Genomic Sys reported earnings per share of -32 cents. This was above the analyst estimate of -34 cents.
Investorplace · 03/19 00:53
Singular Genomics Systems Inc reports results for the quarter ended in December - Earnings Summary
Singular Genomics Systems Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 32 cents per share. Revenue rose 41.3% to $1.08 million from the same quarter last year. The mean expectation of three analysts was for a loss of 34 cents.
Reuters · 03/18 21:02
Singular Genomics Sys: Q4 Earnings Insights
Singular Genomics Sys reported its Q4 earnings on March 18. The company beat estimates by 6.0%. The company's revenue was up $316 thousand from the same period last year. Singular Genomic Sys is expected to announce its earnings Monday, March 18 at 4:05pm.
Benzinga · 03/18 20:40
Singular Genomics Systems GAAP EPS of -$0.32 beats by $0.02, revenue of $1.1M beats by $0.06M
Seeking Alpha · 03/18 20:11
*Singular Genomics Systems 4Q Rev $1.08M >OMIC
Dow Jones · 03/18 20:06
*Singular Genomics Systems 4Q Loss/Shr 32c >OMIC
Dow Jones · 03/18 20:06
BRIEF-Singular Genomics Systems Q4 EPS USD -0.32
Reuters · 03/18 20:05
Press Release: Singular Genomics Reports Recent Highlights and Fourth Quarter and Full Year 2023 Financial Results
Singular Genomics Reports Recent Highlights and Fourth Quarter and Full Year 2023 Financial Results. The company generated revenue of $1.1 million in the fourth quarter of 2023. The G4X is the first in situ spatial sequencer with industry-leading throughput and cost. The company is leveraging novel next-generation sequencing and spatial multiomics technologies.
Dow Jones · 03/18 20:05
Press Release: Singular Genomics Reports Recent -2-
Singular Genomics Systems, Inc. Has a net loss for the three months ended December 31, 2017. The company has no debt. The Company has a positive free cash flow and a positive cash flow from operations. The company expects to earn $1.5 million in the first quarter of 2018 and $2 million in 2018.
Dow Jones · 03/18 20:05
Earnings Scheduled For March 18, 2024
Niu Techs (NASDAQ:NIU) is expected to report earnings for its fourth quarter. Embraer is estimated to report quarterly earnings at $0.53 per share on revenue of $2.00 billion. Companies Reporting Before The Bell include System1 and Nano Labs.
Benzinga · 03/18 09:57
Weekly Report: what happened at OMIC last week (0311-0315)?
Weekly Report · 03/18 09:30
More
Webull provides a variety of real-time OMIC stock news. You can receive the latest news about Singular Genomics Systems, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About OMIC
Singular Genomics Systems, Inc. is a life science technology company that develops next-generation sequencing (NGS) and multiomics technologies. The Company has developed NGS technology (Sequencing Engine), which is a platform technology for its products. The core of its Sequencing Engine consists of proprietary chemistry, including novel chemical compounds, polymers, and enzymes. Its active product development pipeline consists of two products, each of which is designed to leverage the Sequencing Engine and purpose-built to address different applications. Its first product, the G4 Sequencing Platform (G4), targets the NGS market. Its second product in development, G4X Spatial Sequencer, which leverages its sequencing technology, applying it as an in-situ readout for transcriptomics, proteomics and fluorescent H&E in tissue, with spatial context and on the same platform as the G4. The Company is also engaged in developing PX, which is a development-stage multiomics platform.